Pfizer

Key TakeawaysNovartis ranks first, with GSK following closely, yet overall progress in access to essential medicines remains stagnant. Only 43% of clinical trials...

Key TakeawaysInitial studies supported Paxlovid’s efficacy in reducing severe COVID-19 outcomes, but recent data suggest more modest results. Economic and safety considerations are...

Key TakeawaysHYMPAVZI™, Pfizer’s new once-weekly subcutaneous treatment, drastically reduces bleeding episodes in hemophilia A and B patients without inhibitors. The FDA-approved therapy simplifies...

Key TakeawaysEtrasimod does not show additional therapeutic benefits over existing ulcerative colitis treatments based on current clinical trials. The cost of Etrasimod is...

Key TakeawaysThe G-BA's benefit assessment of Isavuconazole (Cresemba) focuses on its efficacy and safety for treating pediatric mucormycosis, a rare but life-threatening fungal...

Key TakeawaysThe EMA has advised suspending a treatment for sickle cell disease Oxbryta's marketing authorization due to emerging safety concerns, urging patients and...

Key TakeawaysPfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine receives a positive recommendation from the European Medicines Agency. The vaccine targets multiple circulating Omicron...

Key HighlightsBRAFTOVI + MEKTOVI combination therapy shows durable responses with an objective response rate (ORR) of 75% and a median duration of response...

Key TakeawaysPonsegromab demonstrated significant improvements in body weight and muscle mass in cancer patients with cachexia. The Phase 2 study met its primary...

Key Takeaways:Acepodia partners with Pfizer Ignite to develop its Antibody-Cell Conjugation (ACC) platform for autoimmune diseases. Pfizer Ignite will provide strategic support in...

Key Takeaways:Pfizer launches PfizerForAll™, a digital platform aimed at making healthcare more accessible and easier to manage for millions of Americans. The platform...

Combination vaccine development by Pfizer and BioNTech has made significant strides, with the companies announcing key results from their Phase 3 clinical trial. The...

The Federal Commission for the Protection against Sanitary Risks (Cofepris) has granted open commercialization approval for Paxlovid (nirmatrelvir/ritonavir), a Pfizer-developed medication used to treat...

RSV or respiratory syncytial virus, presents a significant health risk, especially to immunocompromised adults who are at an increased risk of developing severe lower...

As sales of COVID-19 vaccines continue to decline, lawsuits associated with these products are on the rise. In the latest legal action, the University...